Search for: "Louisiana v. Price"
Results 401 - 420
of 498
Sorted by Relevance
|
Sort by Date
20 Nov 2017, 1:14 pm
In Bigelow v. [read post]
29 Aug 2022, 9:05 pm
Outside of this directive, the agencies generally have taken the view that prior enforcement of the antitrust laws was too lax and that the narrow focus on more traditional antitrust harms (such as higher prices, reduced output, or lower quality) has been too narrow. [read post]
1 May 2015, 9:19 am
Louisiana, 14-280, so that doesn’t really explain the relist. [read post]
15 Dec 2023, 6:34 am
CAAF held in 2023 in United States v. [read post]
25 Nov 2008, 5:04 am
Green v. [read post]
10 Aug 2012, 10:48 am
Soaring price of copyrights led to financial losses for domestic video websites and drove prices of exclusive licenses up. [read post]
17 Jan 2022, 10:53 am
By 1982, every state except for Louisiana had implemented some version of a CON program. [read post]
22 Jan 2020, 6:00 am
They do this by decreasing both supply and demand for a product via price increases. [read post]
23 Aug 2010, 4:15 am
See, e.g., Fitzgerald v. [read post]
23 Feb 2021, 10:05 pm
Let’s say that you have a case that you previously handled called Smith v Acme and now you have a new case called Jones v Acme. [read post]
14 Mar 2016, 2:56 am
In Hantz Financial Services, Inc. v. [read post]
3 Jul 2022, 7:15 am
Supreme Court overturned Roe v. [read post]
31 Mar 2021, 1:32 pm
Of Univ. of Ill. v. [read post]
2 Jan 2014, 9:25 am
Case citation: Sen v. [read post]
17 Jun 2021, 9:45 pm
The Education Department’s announcement comes a year after Bostock v. [read post]
12 Jan 2012, 3:04 pm
In Moeller v. [read post]
31 Mar 2021, 1:32 pm
Of Univ. of Ill. v. [read post]
20 Dec 2019, 2:00 am
Supreme Court’s South Dakota v. [read post]
25 Jan 2008, 1:00 am
: (Generic Pharmaceuticals & IP),Arava (Leflunomide) - Sanofi-Aventis loses bid to dismiss Louisiana Wholsesale Drug Co's antitrust claims accusing S-A of unlawfully blocking generic competition for Arava by filing a sham Citizen Petition with the USFDA: (IP Law360),Ciprofloxacin - CIPLA issued notice by National Pharmaceutical Pricing Authority for allegedly overpricing its antibiotic Ciprofloxacin (especially of note because CIPLA … [read post]
